One Year On, US FDA Generic Drug Cluster Focuses On Facilitating Collaboration
Group Has Made Significant Progress Regarding Data Sharing
Executive Summary
Following its inaugural year, the FDA’s Generic Drug Cluster has formed data sharing arrangements concerning a number of vital indications.
You may also be interested in...
Global Harmonization Efforts Must Go Further
With global regulation of off-patent medicines continuing to evolve, IGBA secretary general Suzette Kox talks about the progress expected from regulatory harmonization for generics and a reduced clinical trial burden for biosimilars.
IGBA Supergroup Gets Audience With WTO
The CEO advisory committee established by the IGBA has held its inaugural meeting and begun discussions with the director-general of the World Trade Organization to promote the “essential role” of generics and biosimilars in global health, with the interaction described as a first step towards a continuing dialog.
IGBA Puts Together Global Leadership Alliance
Leaders from a host of the world’s top generics and biosimilars companies have come together as part of a CEO advisory committee put together by the IGBA. The committee is expected to provide a forum to share thinking on key issues affecting the off-patent industry and best position the industry on critical policy issues with a single collective voice.